Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | LOX | P28300 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29026979 | 0.88 | LOX (0.53) | HDAC6LOXLOXL2ACACBROCK1 | |
| SCHEMBL15651656 | 0.85 | LOX (0.58) | HDAC6LOXLOXL2LRRK2ACACB | |
| SCHEMBL8277607 | 0.84 | HDAC6 (0.50) | HDAC6LOXLOXL2LRRK2ACACB | |
| SCHEMBL3323298 | 0.81 | HDAC6 (0.50) | HDAC6LOXLOXL2LRRK2ACACB | |
| SCHEMBL4932984 | 0.80 | LOXL2 (0.74) | HDAC6LOXLOXL2LRRK2ACACB | |
| SCHEMBL12261864 | 0.80 | HDAC6 (0.47) | HDAC6LOXLOXL2LRRK2ACACB | |
| SCHEMBL16217410 | 0.80 | HDAC6 (0.50) | HDAC6LOXLOXL2LRRK2ACACB | |
| SCHEMBL16220848 | 0.80 | LOX (0.54) | HDAC6LOXLOXL2LRRK2ACACB | |
| SCHEMBL21311492 | 0.79 | LOX (0.46) | LOXLOXL2LRRK2ACACB | |
| SCHEMBL22583032 | 0.77 | NOS3 (0.47) | HDAC6LRRK2ROCK1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| EP-2247591-A1 | PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| WO-2009098236-A1 | PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | HDAC6 705/4885LOX 1029/4885LOXL2 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.